TNFRSF9 and neoplasm: Moreover, after upregulation of CD137 expression in NK cells, we showed that stimulation of this target with rhCD137L enhanced NK cell activity, as measured by cytotoxicity and release of cytokines, toward trastuzumab-bound tumor cells.